NB Health Laboratory Co., Ltd

3:15 PM - 3:30 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Since 2008, NBHL has focused on establishing a technology platform for the generation of functional mAbs targeting GPCRs to pioneer a new field in GPCR-targeted drug discovery, in collaboration with universities and other partners in Japan. The result is a proprietary technology platform, which is now attracting interest for its potential to be used for the generation of therapeutic antibodies.
NBHL has used the technology platform to discover promising mAbs targeting GPCRs for the treatment of respiratory diseases ,chronic inflammation, infection, ocular and immune-oncology which are being progressed towards clinical development.
NBHL’s core business model is to provide the pharmaceutical industry with innovative drug candidates, including mAbs targeting GPCRs and small molecules. Through collaborations with pharmaceutical companies, NBHL operates its proprietary technology platform to run drug discovery programs according to specifications provided by its customers.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
mAb for lung fibrosis and lung cancer
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3